Recent developments in weight loss treatments highlight the growing impact of GLP-1 (glucagon-like peptide-1) therapies, which are reshaping obesity management and preventive healthcare. These pharmacological interventions mimic natural gut hormones, regulating appetite, glucose metabolism, and energy balance, leading to significant and sustained weight reduction in clinical trials. Physicians are increasingly integrating GLP-1 analogs alongside lifestyle interventions, targeting patients with obesity-related comorbidities such as diabetes, hypertension, and cardiovascular risk.